PMV Pharma reports 34% ORR in 103 evaluable patients across all cohorts.
ByAinvest
Friday, Oct 24, 2025 11:45 am ET1min read
PMVP--
PMV Pharmaceuticals presented data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, showing a 34% overall response rate among 103 evaluable patients across eight tumor types. The median duration of response was 7.6 months. A 46% response rate was observed in the ovarian cancer cohort, with a median duration of response of 8.0 months. A New Drug Application submission for platinum-resistant/refractory ovarian cancer is planned for the first quarter of 2027.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet